Von der Industrie gesponserte klinische Studien am Neuroscience MR: 


Axon CO 18700: A 3-months randomized, placebo-controlled, parallel group, double-blinded, multi-centre, phase I study to assess tolerability and safety of AADvac1 applied to patients with mild to moderate Alzheimer’s disease with a 3-months open label extension period, Sponsor: AXON Neuroscience SE

Axon Phase II Study ADAMANT: Alzheimer’s Disease Active immunization: disease-Modifying treatment by Axon Neuroscience directed against Tau: A 24-months randomized, placebo-controlled, parallel group, double-blinded, multi-centre, phase II study to assess safety and efficacy of AADvac1 applied to patients with mild Alzheimer’s disease, Sponsor: AXON Neuroscience SE

ENGAGE: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease, Sponsor: Biogen

ORATORIO: A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis, Sponsor: Hoffmann-La Roche

CFTY720: A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis, Phase IIIb, Sponsor: Novartis

GAM27: Active-controlled phase IIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis, Sponsor: Octapharma

MESEMS: Randomised, double-blind, cross-over, phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria), Sponsor: SALK

ENSEMBLE MA30143: An open-label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting Multiple Sclerosis, Phase IIIb, in Vorbereitung, Sponsor: Hoffman-La Roche

HEP: Human Epilepsy Project: Six-year, prospective, multicenter observational study whose primary goal is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with newly treated focal epilepsy, Sponsor: The Epilepsy Study Consortium

BIA-2093-311: Wirksamkeit und Sicherheit von Eslicarbazepin Acetat als Monotherapie für Patienten mit neu diagnostizierten fokal beginnenden Anfällen, Phase III, Sponsor: BIAL-Portela

WAKE-UP: Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial, Sponsor: University Medical Center Hamburg-Eppendorf

Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft mbH | Müllner Hauptstraße 48 | A-5020 Salzburg
Telefon: +43 (0)5 7255-0 | © 2013-2024
Impressum Informationssicherheit Datenschutz AGB
Letzte Änderung: 23.02.2024
x schließen